NCT03576417: Phase 3: (NIVOPOSTOP) - Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
First Posted 2018-07-03 Trial status Active, not recruiting Sponsor Groupe Oncologie Radiotherapie Tete et Cou Abstract Presentation NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details Press Release GORTEC Announces New Trial Suc
Jun 29, 2025